Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Early neuronal accumulation of DNA double strand breaks in Alzheimer's disease.

Shanbhag NM, Evans MD, Mao W, Nana AL, Seeley WW, Adame A, Rissman RA, Masliah E, Mucke L.

Acta Neuropathol Commun. 2019 May 17;7(1):77. doi: 10.1186/s40478-019-0723-5.

2.

Fibrinogen Induces Microglia-Mediated Spine Elimination and Cognitive Impairment in an Alzheimer's Disease Model.

Merlini M, Rafalski VA, Rios Coronado PE, Gill TM, Ellisman M, Muthukumar G, Subramanian KS, Ryu JK, Syme CA, Davalos D, Seeley WW, Mucke L, Nelson RB, Akassoglou K.

Neuron. 2019 Mar 20;101(6):1099-1108.e6. doi: 10.1016/j.neuron.2019.01.014. Epub 2019 Feb 5.

PMID:
30737131
3.

Klotho controls the brain-immune system interface in the choroid plexus.

Zhu L, Stein LR, Kim D, Ho K, Yu GQ, Zhan L, Larsson TE, Mucke L.

Proc Natl Acad Sci U S A. 2018 Nov 27;115(48):E11388-E11396. doi: 10.1073/pnas.1808609115. Epub 2018 Nov 9.

4.

The integration site of the APP transgene in the J20 mouse model of Alzheimer's disease.

Tosh JL, Rickman M, Rhymes E, Norona FE, Clayton E, Mucke L, Isaacs AM, Fisher EMC, Wiseman FK.

Version 2. Wellcome Open Res. 2018 Oct 10 [revised 2018 Jan 1];2:84. doi: 10.12688/wellcomeopenres.12237.2. eCollection 2017.

5.

Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration.

Ryu JK, Rafalski VA, Meyer-Franke A, Adams RA, Poda SB, Rios Coronado PE, Pedersen LØ, Menon V, Baeten KM, Sikorski SL, Bedard C, Hanspers K, Bardehle S, Mendiola AS, Davalos D, Machado MR, Chan JP, Plastira I, Petersen MA, Pfaff SJ, Ang KK, Hallenbeck KK, Syme C, Hakozaki H, Ellisman MH, Swanson RA, Zamvil SS, Arkin MR, Zorn SH, Pico AR, Mucke L, Freedman SB, Stavenhagen JB, Nelson RB, Akassoglou K.

Nat Immunol. 2018 Nov;19(11):1212-1223. doi: 10.1038/s41590-018-0232-x. Epub 2018 Oct 15.

6.

The mouse as a model for neuropsychiatric drug development.

Howe JR 6th, Bear MF, Golshani P, Klann E, Lipton SA, Mucke L, Sahin M, Silva AJ.

Curr Biol. 2018 Sep 10;28(17):R909-R914. doi: 10.1016/j.cub.2018.07.046.

PMID:
30205056
7.

The Psychiatric Cell Map Initiative: A Convergent Systems Biological Approach to Illuminating Key Molecular Pathways in Neuropsychiatric Disorders.

Willsey AJ, Morris MT, Wang S, Willsey HR, Sun N, Teerikorpi N, Baum TB, Cagney G, Bender KJ, Desai TA, Srivastava D, Davis GW, Doudna J, Chang E, Sohal V, Lowenstein DH, Li H, Agard D, Keiser MJ, Shoichet B, von Zastrow M, Mucke L, Finkbeiner S, Gan L, Sestan N, Ward ME, Huttenhain R, Nowakowski TJ, Bellen HJ, Frank LM, Khokha MK, Lifton RP, Kampmann M, Ideker T, State MW, Krogan NJ.

Cell. 2018 Jul 26;174(3):505-520. doi: 10.1016/j.cell.2018.06.016. Review.

PMID:
30053424
8.

Neuronal levels and sequence of tau modulate the power of brain rhythms.

Das M, Maeda S, Hu B, Yu GQ, Guo W, Lopez I, Yu X, Tai C, Wang X, Mucke L.

Neurobiol Dis. 2018 Sep;117:181-188. doi: 10.1016/j.nbd.2018.05.020. Epub 2018 May 31.

PMID:
29859869
9.

Nav1.1-Overexpressing Interneuron Transplants Restore Brain Rhythms and Cognition in a Mouse Model of Alzheimer's Disease.

Martinez-Losa M, Tracy TE, Ma K, Verret L, Clemente-Perez A, Khan AS, Cobos I, Ho K, Gan L, Mucke L, Alvarez-Dolado M, Palop JJ.

Neuron. 2018 Apr 4;98(1):75-89.e5. doi: 10.1016/j.neuron.2018.02.029. Epub 2018 Mar 15.

10.

Istradefylline reduces memory deficits in aging mice with amyloid pathology.

Orr AG, Lo I, Schumacher H, Ho K, Gill M, Guo W, Kim DH, Knox A, Saito T, Saido TC, Simms J, Toddes C, Wang X, Yu GQ, Mucke L.

Neurobiol Dis. 2018 Feb;110:29-36. doi: 10.1016/j.nbd.2017.10.014. Epub 2017 Oct 31.

11.

Phosphorylation of tau at Y18, but not tau-fyn binding, is required for tau to modulate NMDA receptor-dependent excitotoxicity in primary neuronal culture.

Miyamoto T, Stein L, Thomas R, Djukic B, Taneja P, Knox J, Vossel K, Mucke L.

Mol Neurodegener. 2017 May 19;12(1):41. doi: 10.1186/s13024-017-0176-x.

12.

Network abnormalities and interneuron dysfunction in Alzheimer disease.

Palop JJ, Mucke L.

Nat Rev Neurosci. 2016 Dec;17(12):777-792. doi: 10.1038/nrn.2016.141. Epub 2016 Nov 10. Review.

PMID:
27829687
13.

Tau Phosphorylation-Much More than a Biomarker.

Maeda S, Mucke L.

Neuron. 2016 Oct 19;92(2):265-267. doi: 10.1016/j.neuron.2016.10.011.

14.

Incidence and impact of subclinical epileptiform activity in Alzheimer's disease.

Vossel KA, Ranasinghe KG, Beagle AJ, Mizuiri D, Honma SM, Dowling AF, Darwish SM, Van Berlo V, Barnes DE, Mantle M, Karydas AM, Coppola G, Roberson ED, Miller BL, Garcia PA, Kirsch HE, Mucke L, Nagarajan SS.

Ann Neurol. 2016 Dec;80(6):858-870. doi: 10.1002/ana.24794. Epub 2016 Nov 7.

15.

Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice.

Maeda S, Djukic B, Taneja P, Yu GQ, Lo I, Davis A, Craft R, Guo W, Wang X, Kim D, Ponnusamy R, Gill TM, Masliah E, Mucke L.

EMBO Rep. 2016 Apr;17(4):530-51. doi: 10.15252/embr.201541438. Epub 2016 Mar 1.

16.

Network dysfunction in α-synuclein transgenic mice and human Lewy body dementia.

Morris M, Sanchez PE, Verret L, Beagle AJ, Guo W, Dubal D, Ranasinghe KG, Koyama A, Ho K, Yu GQ, Vossel KA, Mucke L.

Ann Clin Transl Neurol. 2015 Oct 16;2(11):1012-28. doi: 10.1002/acn3.257. eCollection 2015 Nov.

17.

DNA repair factor BRCA1 depletion occurs in Alzheimer brains and impairs cognitive function in mice.

Suberbielle E, Djukic B, Evans M, Kim DH, Taneja P, Wang X, Finucane M, Knox J, Ho K, Devidze N, Masliah E, Mucke L.

Nat Commun. 2015 Nov 30;6:8897. doi: 10.1038/ncomms9897.

18.
19.

Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.

Morris M, Knudsen GM, Maeda S, Trinidad JC, Ioanoviciu A, Burlingame AL, Mucke L.

Nat Neurosci. 2015 Aug;18(8):1183-9. doi: 10.1038/nn.4067. Epub 2015 Jul 20.

PMID:
26192747
20.

Tau reduction prevents Aβ-induced axonal transport deficits by blocking activation of GSK3β.

Vossel KA, Xu JC, Fomenko V, Miyamoto T, Suberbielle E, Knox JA, Ho K, Kim DH, Yu GQ, Mucke L.

J Cell Biol. 2015 May 11;209(3):419-33. doi: 10.1083/jcb.201407065.

21.

Dynamin-related protein 1 is required for normal mitochondrial bioenergetic and synaptic function in CA1 hippocampal neurons.

Shields LY, Kim H, Zhu L, Haddad D, Berthet A, Pathak D, Lam M, Ponnusamy R, Diaz-Ramirez LG, Gill TM, Sesaki H, Mucke L, Nakamura K.

Cell Death Dis. 2015 Apr 16;6:e1725. doi: 10.1038/cddis.2015.94.

22.

Life extension factor klotho prevents mortality and enhances cognition in hAPP transgenic mice.

Dubal DB, Zhu L, Sanchez PE, Worden K, Broestl L, Johnson E, Ho K, Yu GQ, Kim D, Betourne A, Kuro-O M, Masliah E, Abraham CR, Mucke L.

J Neurosci. 2015 Feb 11;35(6):2358-71. doi: 10.1523/JNEUROSCI.5791-12.2015.

23.

Astrocytic adenosine receptor A2A and Gs-coupled signaling regulate memory.

Orr AG, Hsiao EC, Wang MM, Ho K, Kim DH, Wang X, Guo W, Kang J, Yu GQ, Adame A, Devidze N, Dubal DB, Masliah E, Conklin BR, Mucke L.

Nat Neurosci. 2015 Mar;18(3):423-34. doi: 10.1038/nn.3930. Epub 2015 Jan 26.

24.

Tau reduction diminishes spatial learning and memory deficits after mild repetitive traumatic brain injury in mice.

Cheng JS, Craft R, Yu GQ, Ho K, Wang X, Mohan G, Mangnitsky S, Ponnusamy R, Mucke L.

PLoS One. 2014 Dec 31;9(12):e115765. doi: 10.1371/journal.pone.0115765. eCollection 2014.

25.

Progranulin protects against amyloid β deposition and toxicity in Alzheimer's disease mouse models.

Minami SS, Min SW, Krabbe G, Wang C, Zhou Y, Asgarov R, Li Y, Martens LH, Elia LP, Ward ME, Mucke L, Farese RV Jr, Gan L.

Nat Med. 2014 Oct;20(10):1157-64. doi: 10.1038/nm.3672. Epub 2014 Sep 28.

26.

Tau reduction prevents disease in a mouse model of Dravet syndrome.

Gheyara AL, Ponnusamy R, Djukic B, Craft RJ, Ho K, Guo W, Finucane MM, Sanchez PE, Mucke L.

Ann Neurol. 2014 Sep;76(3):443-56. doi: 10.1002/ana.24230. Epub 2014 Aug 13.

27.

Life extension factor klotho enhances cognition.

Dubal DB, Yokoyama JS, Zhu L, Broestl L, Worden K, Wang D, Sturm VE, Kim D, Klein E, Yu GQ, Ho K, Eilertson KE, Yu L, Kuro-o M, De Jager PL, Coppola G, Small GW, Bennett DA, Kramer JH, Abraham CR, Miller BL, Mucke L.

Cell Rep. 2014 May 22;7(4):1065-76. doi: 10.1016/j.celrep.2014.03.076. Epub 2014 May 10.

28.

Seizures and epileptiform activity in the early stages of Alzheimer disease.

Vossel KA, Beagle AJ, Rabinovici GD, Shu H, Lee SE, Naasan G, Hegde M, Cornes SB, Henry ML, Nelson AB, Seeley WW, Geschwind MD, Gorno-Tempini ML, Shih T, Kirsch HE, Garcia PA, Miller BL, Mucke L.

JAMA Neurol. 2013 Sep 1;70(9):1158-66. doi: 10.1001/jamaneurol.2013.136.

29.

Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-β.

Suberbielle E, Sanchez PE, Kravitz AV, Wang X, Ho K, Eilertson K, Devidze N, Kreitzer AC, Mucke L.

Nat Neurosci. 2013 May;16(5):613-21. doi: 10.1038/nn.3356. Epub 2013 Mar 24.

30.

Age-appropriate cognition and subtle dopamine-independent motor deficits in aged tau knockout mice.

Morris M, Hamto P, Adame A, Devidze N, Masliah E, Mucke L.

Neurobiol Aging. 2013 Jun;34(6):1523-9. doi: 10.1016/j.neurobiolaging.2012.12.003. Epub 2013 Jan 16.

31.

Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits.

Harris JA, Koyama A, Maeda S, Ho K, Devidze N, Dubal DB, Yu GQ, Masliah E, Mucke L.

PLoS One. 2012;7(9):e45881. doi: 10.1371/journal.pone.0045881. Epub 2012 Sep 24.

32.

Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.

Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu GQ, Palop JJ, Mucke L.

Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):E2895-903. doi: 10.1073/pnas.1121081109. Epub 2012 Aug 6.

33.

Neurotoxicity of amyloid β-protein: synaptic and network dysfunction.

Mucke L, Selkoe DJ.

Cold Spring Harb Perspect Med. 2012 Jul;2(7):a006338. doi: 10.1101/cshperspect.a006338. Review.

34.

Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model.

Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K, Devidze N, Masliah E, Kreitzer AC, Mody I, Mucke L, Palop JJ.

Cell. 2012 Apr 27;149(3):708-21. doi: 10.1016/j.cell.2012.02.046.

35.

Alzheimer mechanisms and therapeutic strategies.

Huang Y, Mucke L.

Cell. 2012 Mar 16;148(6):1204-22. doi: 10.1016/j.cell.2012.02.040. Review.

36.

Selective targeting of microglia by quantum dots.

Minami SS, Sun B, Popat K, Kauppinen T, Pleiss M, Zhou Y, Ward ME, Floreancig P, Mucke L, Desai T, Gan L.

J Neuroinflammation. 2012 Jan 24;9:22. doi: 10.1186/1742-2094-9-22.

37.

Tau reduction does not prevent motor deficits in two mouse models of Parkinson's disease.

Morris M, Koyama A, Masliah E, Mucke L.

PLoS One. 2011;6(12):e29257. doi: 10.1371/journal.pone.0029257. Epub 2011 Dec 19.

38.

Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice.

Cissé M, Sanchez PE, Kim DH, Ho K, Yu GQ, Mucke L.

J Neurosci. 2011 Jul 20;31(29):10427-31. doi: 10.1523/JNEUROSCI.1459-11.2011. Erratum in: J Neurosci. 2011 Sep 28;31(39):14046.

39.

The many faces of tau.

Morris M, Maeda S, Vossel K, Mucke L.

Neuron. 2011 May 12;70(3):410-26. doi: 10.1016/j.neuron.2011.04.009. Review.

40.

Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease.

Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu GQ, Palop JJ, Noebels JL, Mucke L.

J Neurosci. 2011 Jan 12;31(2):700-11. doi: 10.1523/JNEUROSCI.4152-10.2011.

41.

Reversing EphB2 depletion rescues cognitive functions in Alzheimer model.

Cissé M, Halabisky B, Harris J, Devidze N, Dubal DB, Sun B, Orr A, Lotz G, Kim DH, Hamto P, Ho K, Yu GQ, Mucke L.

Nature. 2011 Jan 6;469(7328):47-52. doi: 10.1038/nature09635. Epub 2010 Nov 28.

42.

Transsynaptic progression of amyloid-β-induced neuronal dysfunction within the entorhinal-hippocampal network.

Harris JA, Devidze N, Verret L, Ho K, Halabisky B, Thwin MT, Kim D, Hamto P, Lo I, Yu GQ, Palop JJ, Masliah E, Mucke L.

Neuron. 2010 Nov 4;68(3):428-41. doi: 10.1016/j.neuron.2010.10.020.

44.

Tau reduction prevents Abeta-induced defects in axonal transport.

Vossel KA, Zhang K, Brodbeck J, Daub AC, Sharma P, Finkbeiner S, Cui B, Mucke L.

Science. 2010 Oct 8;330(6001):198. doi: 10.1126/science.1194653. Epub 2010 Sep 9.

45.

Cellular source of apolipoprotein E4 determines neuronal susceptibility to excitotoxic injury in transgenic mice.

Buttini M, Masliah E, Yu GQ, Palop JJ, Chang S, Bernardo A, Lin C, Wyss-Coray T, Huang Y, Mucke L.

Am J Pathol. 2010 Aug;177(2):563-9. doi: 10.2353/ajpath.2010.090973. Epub 2010 Jul 1.

46.

Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks.

Palop JJ, Mucke L.

Nat Neurosci. 2010 Jul;13(7):812-8. doi: 10.1038/nn.2583. Review.

47.

Phospholipase A2 and arachidonic acid in Alzheimer's disease.

Sanchez-Mejia RO, Mucke L.

Biochim Biophys Acta. 2010 Aug;1801(8):784-90. doi: 10.1016/j.bbalip.2010.05.013. Epub 2010 May 27. Review.

48.

Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein.

Harris JA, Devidze N, Halabisky B, Lo I, Thwin MT, Yu GQ, Bredesen DE, Masliah E, Mucke L.

J Neurosci. 2010 Jan 6;30(1):372-81. doi: 10.1523/JNEUROSCI.5341-09.2010.

49.

Imbalance between GABAergic and Glutamatergic Transmission Impairs Adult Neurogenesis in an Animal Model of Alzheimer's Disease.

Sun B, Halabisky B, Zhou Y, Palop JJ, Yu G, Mucke L, Gan L.

Cell Stem Cell. 2009 Dec 4;5(6):624-33. doi: 10.1016/j.stem.2009.10.003.

50.

Synaptic depression and aberrant excitatory network activity in Alzheimer's disease: two faces of the same coin?

Palop JJ, Mucke L.

Neuromolecular Med. 2010 Mar;12(1):48-55. doi: 10.1007/s12017-009-8097-7. Epub 2009 Oct 17. Review.

Supplemental Content

Support Center